健民药业集团股份有限公司2026年第一季度报告详细解读

主要财务亮点

• 营业收入：2026年第一季度实现营业收入8.73亿元，同比下降2.13%。
• 归属于上市公司股东的净利润：为8,773万元，同比大幅下降20.37%。
• 扣除非经常性损益后净利润：为7,633万元，同比下降25.94%。
• 利润总额：9,754万元，同比下降21.83%。
• 每股收益：基本每股收益和稀释每股收益均为0.58元，同比下降20.55%。
• 加权平均净资产收益率：为3.25%，同比减少1.17个百分点。
• 经营活动现金流量净额：为4,581万元，实现同比大幅增长283.83%，主要因采购付款减少。

非经常性损益情况

• 非经常性损益合计：本期为1,140万元，主要包括政府补助（613万元）、金融资产公允价值变动及处置（725万元）、资产处置损益（8.6万元），及营业外收入与支出。
• 所得税影响：非经常性损益扣除所得税影响额200万元。

财务状况分析

• 资产总额：截至2026年3月31日，总资产为46.88亿元，较年初增长3.57%。
• 归属于上市公司股东的所有者权益：为27.44亿元，较年初增加3.30%。
• 流动资产：包括货币资金（1.62亿元）、交易性金融资产（9.66亿元）、应收账款（9.09亿元）、存货（3.28亿元）。
• 流动负债：合计18.07亿元，主要包括短期借款（2,000万元）、应付账款（5.13亿元）、合同负债（2,645万元）、其他流动负债（7.71亿元）。
• 非流动负债：合计1.16亿元，主要包括长期借款（3,430万元）、租赁负债（3,445万元）、递延收益（4,214万元）。

利润组成及变化原因

• 营业成本：本期营业成本较去年同期大幅下降，表明毛利率有一定改善。
• 销售费用：本期销售费用4.19亿元，较去年同期增长16%，显示公司加大市场推广及销售力度。
• 投资收益：本期投资收益1,369万元，较去年同期大幅减少，主要系联营企业带来投资收益减少。
• 管理费用及研发费用：管理费用为4,658万元，基本与去年持平；研发费用为2,127万元也基本持平。
• 现金流：经营活动现金流显著改善，采购付款减少是主要原因。

股东结构与持股情况

• 普通股股东总数：报告期末为21,395人。
• 前十大股东：华立医药集团有限公司持股24.13%，香港中央结算有限公司持股3.65%，华立集团股份有限公司持股3.32%，其余为自然人及机构投资者，前十大股东合计持股比例显著，且华立医药集团与华立集团为一致行动人。
• 融资融券：部分自然人股东通过信用担保账户持股，表明公司股票活跃于融资融券市场。

现金流量表核心信息

• 经营活动现金流入8.49亿元，现金流出8.04亿元，净流入4,581万元。
• 投资活动现金流净额3,969万元，较去年大幅减少。
• 筹资活动现金流净额为-4,162万元，主要因偿还债务。
• 期末现金及现金等价物余额为1.56亿元。

潜在影响及投资者需关注事项

• 利润大幅下滑：归属于上市公司股东的净利润同比下降20.37%，扣非净利润降幅更大，显示公司主营业务及投资收益均面临压力，可能对公司股价造成负面影响。
• 投资收益减少：联营企业带来的投资收益减少，是利润下滑主要原因之一，需持续关注相关企业经营状况。
• 销售费用显著增加：销售费用同比增长16%，反映公司扩大营销投入，但短期对盈利有压力，长期需观察效果。
• 经营现金流大幅改善：采购付款减少导致经营现金流转为正，表明公司资金管理改善，有助于缓解短期资金压力。
• 股东结构稳定：主要股东未出现大幅变动，华立集团及其子公司仍为最大控股方，股权结构较为集中。

结论

健民药业集团2026年第一季度报告显示，公司盈利能力较去年同期明显下降，主要受投资收益减少及销售费用增长影响。虽然经营现金流大幅改善，有助于短期资金状况，但利润下滑或对公司股价带来压力。投资者需重点关注公司后续投资收益情况，以及销售费用增长带来的长期效果。股东结构稳定，控股股东地位未变。整体来看，报告中利润下滑、投资收益减少等信息属价格敏感，建议投资者密切关注公司后续经营动态。

免责声明：本文仅为基于公司2026年第一季度报告的分析，不构成任何投资建议。请投资者根据自身情况谨慎决策。

Jianmin Pharmaceutical Group Co., Ltd. 2026 Q1 Report Detailed Analysis

Key Financial Highlights

• Revenue: RMB 873 million in Q1 2026, down 2.13% year-on-year.
• Net profit attributable to shareholders: RMB 87.73 million, down 20.37% year-on-year.
• Net profit after non-recurring items: RMB 76.33 million, down 25.94% year-on-year.
• Total profit: RMB 97.54 million, down 21.83% year-on-year.
• EPS: Basic and diluted EPS both RMB 0.58, down 20.55% year-on-year.
• Weighted ROE: 3.25%, down 1.17 percentage points year-on-year.
• Net cash flow from operations: RMB 45.82 million, up 283.83%, mainly due to reduced procurement payments.

Non-recurring Profit & Loss

• Total non-recurring profit/loss: RMB 11.40 million, mainly from government subsidies (RMB 6.13 million), financial asset fair value changes/disposal (RMB 7.25 million), asset disposal gains (RMB 86,000), and other income/expenses.
• Tax impact: Deducted RMB 2.01 million in taxes from non-recurring items.

Financial Position

• Total assets: RMB 4.69 billion as of March 31, 2026, up 3.57% from year start.
• Shareholders’ equity: RMB 2.74 billion, up 3.30% from year start.
• Key current assets: cash (RMB 161 million), trading financial assets (RMB 966 million), receivables (RMB 909 million), inventory (RMB 328 million).
• Key current liabilities: RMB 1.81 billion, including short-term loans (RMB 20 million), payables (RMB 513 million), contract liabilities (RMB 26 million), other current liabilities (RMB 771 million).
• Non-current liabilities: RMB 115 million, including long-term loans (RMB 34 million), lease liabilities (RMB 34 million), deferred income (RMB 42 million).

Profit Structure & Reasons for Changes

• Operating costs: Significantly down vs last year, suggesting improved gross margin.
• Sales expenses: Up 16% to RMB 419 million, reflecting increased market investment.
• Investment income: Down sharply to RMB 13.69 million, mainly due to lower returns from associates.
• Management & R&D expenses: Flat vs last year.
• Cash flow: Operating cash flow improved greatly, mainly due to reduced procurement payments.

Shareholding Structure

• Ordinary shareholders: 21,395 at period end.
• Top 10 shareholders: Huali Pharmaceutical Group holds 24.13%, Hong Kong Central Clearing 3.65%, Huali Group 3.32%, others are individuals and institutional investors. Huali Pharmaceutical and Huali Group are acting together.
• Margin trading: Some individual shareholders hold shares via margin accounts.

Cash Flow Highlights

• Cash inflow from operations: RMB 849 million; outflow: RMB 803 million; net inflow: RMB 45.82 million.
• Investing cash flow net: RMB 39.7 million, down sharply from last year.
• Financing cash flow net: RMB -41.6 million, mainly due to debt repayment.
• Ending cash balance: RMB 156 million.

Potential Impact & Key Investor Takeaways

• Profit sharp decline: Net profit attributable to shareholders fell 20.37%, with greater drop after non-recurring items. This could negatively affect share price.
• Investment income drop: Lower returns from associates are a key reason for profit decline. Investors should monitor these associates closely.
• Sales expenses surge: Up 16%, reflecting aggressive marketing. Short-term pressure on profit, long-term effect needs observation.
• Operating cash flow improved: Cash management improved, providing better short-term liquidity.
• Shareholding stable: No major changes among key shareholders; control remains concentrated.

Conclusion

Jianmin Pharmaceutical’s Q1 2026 report shows a significant drop in profit, mainly due to reduced investment income and higher sales expenses. Operating cash flow improved, easing short-term liquidity. However, profit decline and investment income drop are price-sensitive and may impact the share price. Investors should closely watch future investment returns and the impact of increased sales expenses. Shareholding remains stable.

Disclaimer: This article is based on the 2026 Q1 report and does not constitute investment advice. Investors should make decisions based on their own circumstances.

View 健民集团 Historical chart here